Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy

By sjmartinez • June 3, 2024

Miller JE, Taylor-Cousar JL, Overdevest JB, Khatiwada A, Mace JC, Alt JA, Bodner TE, Chowdhury NI, DiMango EA, Eshaghian PH, Getz AE, Gudis DA, Han EJ, Hwang PH, Keating CL, Khanwalkar A, Kimple AJ, Lee JT, Li D, Markarian K, Norris M, Nayak JV, Owens C, Patel ZM, Poch K, Schlosser RJ, Smith KA, Smith TL, Soler ZM, Suh JD, Tervo JP, Turner GA, Wang MB, Saavedra MT, Beswick DM. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy. Int Forum Allergy Rhinol. 2024 Jun;14(6):1079-1087. doi: 10.1002/alr.23312. Epub 2023 Dec 25. PMID: 38145393.

Tags: chronic rhinosinusitis, cystic fibrosis, highly effective modulator therapy, olfaction, olfactory disorders, olfactory dysfunction, olfactory test, patient‐reported outcome measure, Publications, Pulmonary, Critical Care & Sleep Medicine, Quality of Life

Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial

Goel K, Lindman BR, Schwartz A, Cohen DJ, Giustino G, Oldemeyer JB, Strote J, Babaliaros V, Devireddy CM, Fischbein MP, Fearon WF, Daniels D, Spies[...]

Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia

Wang ES, Erba HP, Zeidan AM, Roboz GJ, Altman JK, Advani AS, Lin TL, Strickland SA, Juckett MB, Pratz KW, Mangan JK, McMahon CM, Alsfeld[...]

Considerations and best practices for respirometry

Ball AB, Stiles L, Divakaruni AS. Considerations and best practices for respirometry. Cell Metab. 2026 Jun 2;38(6):1093-1096. doi: 10.1016/j.cmet.2026.05.001. PMID: 42229405.